Drug Profile


Alternative Names: Beleodaq; CLN-9; PDX 101; PX-105684; PXD 101

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TopoTarget
  • Developer CIMA- Universidad de Navarra; Emory University; National Cancer Institute (USA); Onxeo SA; Spectrum Pharmaceuticals; TopoTarget
  • Class Acrylamides; Antineoplastics; Hydroxamic acids; Small molecules; Sulfonamides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Thymoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase II B cell lymphoma; Glioblastoma
  • Phase I/II Non-small cell lung cancer
  • Phase I Acute myeloid leukaemia; Lymphoma; Myelodysplastic syndromes; Small cell lung cancer; Solid tumours
  • Preclinical Hepatocellular carcinoma
  • No development reported Bladder cancer; Carcinoma; Colorectal cancer; Cutaneous T cell lymphoma; Fallopian tube cancer; Mesothelioma; Ovarian cancer; Peritoneal cancer; Soft tissue sarcoma; Thymoma
  • Discontinued Multiple myeloma

Most Recent Events

  • 25 Oct 2017 TopoTarget and the National Cancer Institute completes a phase I pharmacokinetics trial in patients with abnormal liver function in USA (IV) (NCT01273155)
  • 02 Oct 2017 Onxeo plans a phase I trial for Cancer (PO) in early 2019
  • 28 Sep 2017 Onxeo files for patent protection for Belinostat (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top